Peptides Studied for Fat Loss: An Evidence-Based Comparison (2026)

Start here

“Fat loss peptide” covers compounds with wildly different amounts of proof. Two have trials in thousands of people and produce the largest weight loss any drug has ever shown. One has strong data for a specific kind of fat in a specific population. Several are sold hard and do almost nothing in trials. This guide ranks them by evidence, not by marketing.

Tier 1: proven in large trials

Tirzepatide (Mounjaro, Zepbound)

Copies two gut hormones, GLP-1 and GIP, in one weekly injection. In SURMOUNT-1, 2,539 adults with obesity lost an average of 20.9% of their body weight over 72 weeks on the top dose, against 3.1% on placebo (Jastreboff et al., 2022). It beat semaglutide head to head. The most effective weight-loss drug ever tested. Full page: tirzepatide.

Semaglutide (Ozempic, Wegovy)

Copies GLP-1 alone. In STEP 1, 1,961 adults lost 14.9% over 68 weeks against 2.4% on placebo (Wilding et al., 2021), and a three-year trial in 17,604 people with heart disease found 20% fewer heart attacks and strokes, which tirzepatide has not yet matched. Full page: semaglutide.

Both share the same fine print. They work by making you eat less, so the weight comes back when you stop: people who stopped semaglutide regained about two-thirds within a year (Rubino et al., 2021). A quarter to a third of what you lose is lean mass. Nausea is common while the dose rises. And the cheap compounded and “research” versions are not the tested drug. See the GLP-1 guide.

Tesamorelin (Egrifta)

A GHRH copy that raises growth hormone, FDA approved for the deep belly fat that builds up in some people with HIV. Two Phase III trials found visceral fat down about 18% by CT scan, with little change in fat under the skin or in lean mass. It is prescribed off-label for age-related belly fat on the same mechanism, without a trial in that group. Full page: tesamorelin.

Tier 2: raises growth hormone, moves fat a little

MK-677 (ibutamoren)

An oral ghrelin mimic with the best human data in the growth hormone class. In a two-year trial in older adults it restored IGF-1 to young-adult levels; fat mass did not fall, and appetite rose. It is a hormone success and a fat-loss failure. Full page: MK-677.

Ipamorelin + CJC-1295

The standard growth hormone stack. The combination produces a larger growth hormone pulse than either alone, shown in humans over hours. No trial has measured what months of it do to body fat. Users report slow changes alongside training and diet, which produce slow changes on their own. Full pages: ipamorelin, CJC-1295.

Growth hormone does mobilize fat, and the evidence for that comes from tesamorelin, where a bigger, more sustained rise produced a measurable effect on one fat depot in one population. The research-chemical stacks give smaller pulses to healthier people and have never been measured.

Tier 3: failed or absent evidence

AOD-9604

A 16-amino-acid fragment of growth hormone designed to burn fat without the hormone’s other effects. Obese mice lost half their fat in 19 days (Heffernan et al., 2001). Then a 24-week trial in about 300 obese adults missed its primary endpoint, and development stopped; the published paper from the program is about safety (Stier et al., 2013). It is very safe and very ineffective. Full page: AOD-9604.

How they work, side by side

	Mechanism	Human evidence for fat loss	Typical effect
Tirzepatide	Appetite and fullness via GLP-1 + GIP	Phase III, thousands	~21% body weight
Semaglutide	Appetite and fullness via GLP-1	Phase III, thousands	~15% body weight
Tesamorelin	Growth hormone → fat breakdown	Phase III, ~800 (HIV)	~18% visceral fat
MK-677	Ghrelin receptor → growth hormone	2-year trial, 65	No fat loss
Ipamorelin + CJC-1295	Growth hormone pulse	None for fat	Unmeasured
AOD-9604	Fat-cell signaling	Phase IIb, ~300, failed	Roughly none

What to keep in mind

Muscle goes with the fat. On the GLP-1 drugs, a large minority of the loss is lean tissue. Lifting and eating protein are the only tools with any evidence for limiting that, and the trials of that question are still running. See the muscle growth guide.

The drug does the work only while you take it. Every weight-loss trial that followed people after stopping found most of the weight returning.

Diet and exercise are still the base. Every Tier 1 trial included them. The drugs added to that base; nobody has tested them as a replacement for it.

These are prescription drugs. The two that work are prescribed and monitored for good reasons: pancreatitis, gallbladder disease, thyroid warnings, and interactions with diabetes drugs are real. See the safety guide.

Frequently Asked Questions

What is the most effective peptide for fat loss?

Tirzepatide, by trial results, with semaglutide close behind. Nothing else is in the same category.

Do growth hormone peptides burn fat?

Growth hormone mobilizes fat, and tesamorelin proves the effect is real for belly fat in one population. The research-chemical stacks have not been measured, and MK-677, the best-studied of them, produced no fat loss in two years.

Does AOD-9604 work?

Not in the one large human trial. Its safety record is excellent; its efficacy record is not.

Can I get these without a prescription?

The ones that work are prescription drugs. Research-vendor versions of semaglutide and tirzepatide carry none of the trial evidence, because nobody has verified what is in the vial.

References

1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. PubMed
2. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PubMed
3. Rubino D, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. PubMed
4. Stier H, et al. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest. PubMed
5. Heffernan MA, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. PubMed

See also

• Peptide
  AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

  AOD-9604 is the tail end of the growth hormone molecule, kept for its fat-burning signal and stripped of everything else. Mice lost half their fat on it; a 300-person human trial missed its primary goal.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.

• Peptide
  Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

  Ipamorelin is a five-amino-acid peptide that mimics ghrelin to release a pulse of growth hormone, and unlike its predecessors does it without raising cortisol, prolactin, or hunger. Human data: one dosing study and one abandoned surgery trial.